CagriSema

Controlled phase 3 human evidence.



Guide prepared November 13, 2026 · profile review dates retained

KEEP IN MIND Evidence applies to the studied formulation, route, population and outcome—not every product sharing a name.

01 What is it?

CagriSema combines cagrilintide, an amylin receptor agonist, with semaglutide, a GLP-1 receptor agonist, in a defined investigational product. It has combination trial evidence, unlike informal stacks. [1]

02 Potential benefits

REDEFINE 1 was a randomized, double-blind, phase 3 trial in adults with overweight or obesity without diabetes. The published trial found greater body-weight reduction with the combination than with placebo. This is evidence for a defined investigational combination, not evidence for improvised mixtures sold under the same name. [1]

03 Evidence & its limits

The cited development program concerns a defined investigational product in selected trial populations. It does not validate improvised mixtures. Regulatory submission is separate from approval, and sponsor disclosures and gastrointestinal adverse effects belong beside the benefit claims. [1]

04 Risks & unknowns

Gastrointestinal adverse events were common in REDEFINE 1 and were reported more often with the combination than with placebo. Long-term safety, cardiovascular outcomes and the final regulatory label remain under evaluation. FDA submission is not approval; this page does not treat CagriSema as an approved U.S. product. [1]

05 Status & scope

A defined investigational combination. A regulatory submission is not approval; improvised mixtures are not the product tested in its trials. [1]

06 The question to ask

Does the evidence match the exact product, route, condition and outcome being discussed? Check the full record and its review dates. This summary is selective; the product label and clinical assessment contain additional warnings and contraindications.

SOURCES / Tap a reference to open

[1] Full evidence record, references and review dates
[2] PubMed / REDEFINE 1, New England Journal of Medicine, 2025
[3] FDA / Drugs@FDA database
[4] ClinicalTrials.gov / REDEFINE 1, NCT05567796

Selective educational summary, not treatment or dosing advice. Existing profile review dates retained; no independent clinical review.